Do you resume zoledronic acid or denosumab at relapse in multiple myeloma?

This is generally a data free zone.

Remember at induction, the overall survival benefit with Zometa is ONLY in patients with myeloma bone disease achieving less than a partial response to induction. The skeletal related event (SRE) risk reduction compared to placebo was dependent on myeloma control ...

The impact of response on survival was based on post-hoc analysis of the UK Myeloma IX trial. Methodologically speaking, when facing a decision whether to act based on the original randomization vs. post-hoc subgroup analysis, it is usually safer to stick to the original allocation.